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Background: Patients (pts) with incomplete administration of AC for colon cancer (CC) likely 
experience inferior survival while oxaliplatin- and capecitabine-containing AC may not improve 
survival for older pts. The influence on AC completion of age, other baseline patient 
characteristics, or regimen characteristics is unknown. We evaluated the association of baseline 
characteristics and planned AC regimen with AC delivery in resected CC pts. 
Methods: This retrospective cohort study identified stage II and III resected CC pts from our 
local VA Medical Center tumor registry who initiated AC between 2004 and 2010. AC delivery 
was measured as percentage of planned cumulative dose (PCD) of 5-fluorouracil or capecitabine 
delivered. Baseline characteristics were demographics, CC stage, travel distance to the treatment 
site (TD), Adult Comorbidity Evaluation-27 score, and labs. We classified AC as 
fluoropyrimidine (oral or IV)-based and as oxaliplatin-containing. Linear regression tested each 
association with PCD. We recorded occurrence of toxicity and death. Cox regression models 
were used for survival analysis. 
Results: Fifty pts (98% male, median age 63) initiated AC for stage II (n=6) or III (n=44) 
disease with median interval from resection to AC of 7.4 weeks. The median PCD was 75%; 
median treatment duration was 5 months. Lower PCD was associated with older age (p=0.05), 
lower GFR (p=0.05), higher TD (p=0.02), lower baseline hemoglobin (p=0.10), and receipt of 
capecitabine (p<0.01). Receipt of capecitabine (p=0.008) and TD (p=0.04) remained 
significantly associated with PCD in a multiple linear regression model. Toxicity was noted for 
78%, and PCD tended to be lower for reported cardiac events (p=0.07). Pts older than 63 had 
inferior survival (HR=4.17, p=0.03). Pts receiving less than 80% PCD tended toward inferior 
survival (HR=4.31, p=0.07). 
Conclusions: Capecitabine-based AC and travel distance were associated with lower PCD, 
which may negatively impact survival. Efficacy of shorter courses of oxaliplatin-based 
chemotherapy is being evaluated elsewhere. Close attention to quality prescribing and 
monitoring practices for capecitabine are recommended. These findings should be confirmed in a 
larger cohort. 
